T3 pharmaceuticals, a Basel -based company focusing on immuno-oncology, closes its second financing round of over CHF12 million. To progress into the clinical phase, T3 appoints Claire Barton as Chief Medical Officer, strengthens its development team and announces the clinical advisory board.